The drug maker on Thursday announced that it has received final approval by the US drug regulator for amphetamine sulfate tablets.The drug is generic version of Evekeo tablets of Arbor Pharmaceuticals. According to IQVIA sales data for the 12-month period ending November 2020, the Evekeo Tablets, achieved annual sales of approximately $21.5 million.
Amphetamine sulfate tablets are used to treat attention-deficit hyperactivity disorder (ADHD) and a sleep disorder called narcolepsy. It is also used as a short-term treatment, along with a reduced calorie diet and exercise, to help lose weight.
Glenmark s current portfolio consists of 168 products authorized for distribution in the US marketplace and 43 ANDA s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.